Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 Enfortumab Vedotin Approved for Recurrent Bladder Cancer January 14, 2020 Load more HOT NEWS Alectinib Approved as an Adjuvant Treatment for Lung Cancer Study presents an AI-guided approach to target cancer antigens Survivor Guest Post: Living Breast-less Girls Become Best Friends In Hospital, Reunite Years Later For “Survivors”...
